Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001438
English
Authors' recommendations:
Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with chronic obstructive pulmonary disease with a FEV1< 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1534
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Androstadienes
- Benzyl Alcohols
- Chlorobenzenes
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.